C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production

Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2469-75. doi: 10.1161/01.ATV.0000241572.05292.fb. Epub 2006 Aug 17.

Abstract

Objective: C-Reactive protein (CRP), a cardiovascular risk marker, could also participate in atherosclerosis. Atherosclerotic plaques express CRP and interleukin (IL)-10, a major antiinflammatory cytokine. IL-10 deficiency results in increased lesion formation, whereas IL-10 delivery attenuates lesions. We tested the effect of CRP on lipopolysaccharide (LPS)-induced IL-10 secretion in human monocyte-derived macrophages (HMDMs).

Methods and results: Incubation of HMDMs with CRP significantly decreased LPS-induced IL-10 mRNA and intracellular and secreted IL-10 protein and destabilized IL-10 mRNA. Also, CRP alone increased secretion of IL-8, IL-6, and tumor necrosis factor from HMDMs and did not inhibit LPS-induced secretion of these cytokines. Fc gamma receptor I antibodies significantly reversed CRP-mediated IL-10 inhibition. CRP significantly decreased intracellular cAMP, phospho-cAMP response element binding protein (pCREB), and adenyl cyclase activity. cAMP agonists reversed CRP-mediated IL-10 inhibition. Overexpression of wild-type and constitutively active CREB in THP-1 cells revealed attenuation of the inhibitory effect of CRP on LPS-induced IL-10 levels. CRP also inhibited hemoglobin:haptoglobin-induced IL-10 and heme oxygenase-1. Furthermore, administration of human CRP to rats significantly decreased IL-10 levels.

Conclusions: This study provides novel evidence that CRP, by decreasing IL-10 alters the antiinflammatory/proinflammatory balance, accentuating inflammation, which is pivotal in atherothrombosis.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenylyl Cyclase Inhibitors
  • Animals
  • Antibodies / pharmacology
  • C-Reactive Protein / pharmacology*
  • CREB-Binding Protein / antagonists & inhibitors
  • Cells, Cultured
  • Cyclic AMP / agonists
  • Cyclic AMP / antagonists & inhibitors*
  • Cyclic AMP / biosynthesis
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • Haptoglobins / pharmacology
  • Heme Oxygenase-1 / antagonists & inhibitors
  • Hemoglobins / pharmacology
  • Humans
  • Interleukin-10 / antagonists & inhibitors*
  • Interleukin-10 / genetics
  • Interleukin-10 / metabolism
  • Interleukin-6 / metabolism
  • Interleukin-8 / metabolism
  • Intracellular Membranes / metabolism
  • Lipopolysaccharides / pharmacology
  • Macrophages / drug effects
  • Macrophages / metabolism*
  • RNA Stability / drug effects
  • RNA, Messenger / antagonists & inhibitors
  • Rats
  • Receptors, IgG / immunology
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Adenylyl Cyclase Inhibitors
  • Antibodies
  • Cyclic AMP Response Element-Binding Protein
  • FCGR1A protein, human
  • Haptoglobins
  • Hemoglobins
  • Interleukin-6
  • Interleukin-8
  • Lipopolysaccharides
  • RNA, Messenger
  • Receptors, IgG
  • Tumor Necrosis Factor-alpha
  • haptoglobin-hemoglobin complex
  • Interleukin-10
  • C-Reactive Protein
  • Cyclic AMP
  • Heme Oxygenase-1
  • CREB-Binding Protein